Literature DB >> 28235803

Biochemical characterization and structure determination of a potent, selective antibody inhibitor of human MMP9.

Todd C Appleby1, Andrew E Greenstein1, Magdeleine Hung1, Albert Liclican1, Maile Velasquez1, Armando G Villaseñor1, Ruth Wang1, Melanie H Wong1, Xiaohong Liu1, Giuseppe A Papalia1, Brian E Schultz1, Roman Sakowicz1, Victoria Smith1, Hyock Joo Kwon2.   

Abstract

Matrix metalloproteinase 9 (MMP9) is a member of a large family of proteases that are secreted as inactive zymogens. It is a key regulator of the extracellular matrix, involved in the degradation of various extracellular matrix proteins. MMP9 plays a pathological role in a variety of inflammatory and oncology disorders and has long been considered an attractive therapeutic target. GS-5745, a potent, highly selective humanized monoclonal antibody inhibitor of MMP9, has shown promise in treating ulcerative colitis and gastric cancer. Here we describe the crystal structure of GS-5745·MMP9 complex and biochemical studies to elucidate the mechanism of inhibition of MMP9 by GS-5745. GS-5745 binds MMP9 distal to the active site, near the junction between the prodomain and catalytic domain, and inhibits MMP9 by two mechanisms. Binding to pro-MMP9 prevents MMP9 activation, whereas binding to active MMP9 allosterically inhibits activity.
© 2017 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  X-ray crystallography; allosteric regulation; antibody; enzyme inhibitor; matrix metalloproteinase (MMP)

Mesh:

Substances:

Year:  2017        PMID: 28235803      PMCID: PMC5399127          DOI: 10.1074/jbc.M116.760579

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

Review 1.  Matrix metalloproteinases.

Authors:  H Nagase; J F Woessner
Journal:  J Biol Chem       Date:  1999-07-30       Impact factor: 5.157

2.  Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases.

Authors:  Q Gao; M J W Meijer; F J G M Kubben; C F M Sier; L Kruidenier; W van Duijn; M van den Berg; R A van Hogezand; C B H W Lamers; H W Verspaget
Journal:  Dig Liver Dis       Date:  2005-08       Impact factor: 4.088

3.  The behavior of matrix metalloproteinase-9 in lymphocytic colitis, collagenous colitis and ulcerative colitis.

Authors:  Gábor Lakatos; Ferenc Sipos; Pál Miheller; István Hritz; Mária Zsófia Varga; Márk Juhász; Béla Molnár; Zsolt Tulassay; László Herszényi
Journal:  Pathol Oncol Res       Date:  2011-06-16       Impact factor: 3.201

4.  A metalloproteinase inhibitor blocks the shedding of soluble cytokine receptors and processing of transmembrane cytokine precursors in human monocytic cells.

Authors:  S Gallea-Robache; V Morand; S Millet; J M Bruneau; N Bhatnagar; S Chouaib; S Roman-Roman
Journal:  Cytokine       Date:  1997-05       Impact factor: 3.861

5.  A novel role of metalloproteinase in cancer-mediated immunosuppression.

Authors:  B C Sheu; S M Hsu; H N Ho; H C Lien; S C Huang; R H Lin
Journal:  Cancer Res       Date:  2001-01-01       Impact factor: 12.701

Review 6.  Matrix metalloproteinase-9 and autoimmune diseases.

Authors:  Maya Ram; Yaniv Sherer; Yehuda Shoenfeld
Journal:  J Clin Immunol       Date:  2006-05-02       Impact factor: 8.317

Review 7.  Strategies for MMP inhibition in cancer: innovations for the post-trial era.

Authors:  Christopher Mark Overall; Carlos López-Otín
Journal:  Nat Rev Cancer       Date:  2002-09       Impact factor: 60.716

8.  Human matrix metalloproteinase-9: activation by limited trypsin treatment and generation of monoclonal antibodies specific for the activated form.

Authors:  M E Duncan; J P Richardson; G I Murray; W T Melvin; J E Fothergill
Journal:  Eur J Biochem       Date:  1998-11-15

9.  Alanine scanning mutagenesis and functional analysis of the fibronectin-like collagen-binding domain from human 92-kDa type IV collagenase.

Authors:  I E Collier; P A Krasnov; A Y Strongin; H Birkedal-Hansen; G I Goldberg
Journal:  J Biol Chem       Date:  1992-04-05       Impact factor: 5.157

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  26 in total

1.  MMP (Matrix Metalloprotease)-9-Producing Monocytes Enable T Cells to Invade the Vessel Wall and Cause Vasculitis.

Authors:  Ryu Watanabe; Toshihisa Maeda; Hui Zhang; Gerald J Berry; Markus Zeisbrich; Robert Brockett; Andrew E Greenstein; Lu Tian; Jörg J Goronzy; Cornelia M Weyand
Journal:  Circ Res       Date:  2018-08-31       Impact factor: 17.367

2.  Safety and Efficacy of Andecaliximab (GS-5745) Plus Gemcitabine and Nab-Paclitaxel in Patients with Advanced Pancreatic Adenocarcinoma: Results from a Phase I Study.

Authors:  Johanna Bendell; Sunil Sharma; Manish R Patel; Kevin S Windsor; Zev A Wainberg; Michael Gordon; Jorge Chaves; Jordan Berlin; Carrie Baker Brachmann; Marianna Zavodovskaya; JieJane Liu; Dung Thai; Pankaj Bhargava; Manish A Shah; Saad A Khan; Alexander Starodub
Journal:  Oncologist       Date:  2020-09-17

3.  Epitope-specific affinity maturation improved stability of potent protease inhibitory antibodies.

Authors:  Tyler Lopez; Chen Chuan; Aaron Ramirez; Kuan-Hui E Chen; Mary Y Lorenson; Chris Benitez; Zahid Mustafa; Henry Pham; Ramon Sanchez; Ameae M Walker; Xin Ge
Journal:  Biotechnol Bioeng       Date:  2018-09-15       Impact factor: 4.530

4.  Protease Inhibition Mechanism of Camelid-like Synthetic Human Antibodies.

Authors:  Dong Hyun Nam; Ki Baek Lee; Evan Kruchowy; Henry Pham; Xin Ge
Journal:  Biochemistry       Date:  2020-09-30       Impact factor: 3.162

Review 5.  New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.

Authors:  Isabel Corraliza-Gorjón; Beatriz Somovilla-Crespo; Silvia Santamaria; Jose A Garcia-Sanz; Leonor Kremer
Journal:  Front Immunol       Date:  2017-12-21       Impact factor: 7.561

Review 6.  Monoclonal antibodies against metzincin targets.

Authors:  Salvatore Santamaria; Rens de Groot
Journal:  Br J Pharmacol       Date:  2018-04-02       Impact factor: 8.739

7.  Ten-gene signature reveals the significance of clinical prognosis and immuno-correlation of osteosarcoma and study on novel skeleton inhibitors regarding MMP9.

Authors:  Weihang Li; Ziyi Ding; Dong Wang; Chengfei Li; Yikai Pan; Yingjing Zhao; Hongzhe Zhao; Tianxing Lu; Rui Xu; Shilei Zhang; Bin Yuan; Yunlong Zhao; Yanjiang Yin; Yuan Gao; Jing Li; Ming Yan
Journal:  Cancer Cell Int       Date:  2021-07-14       Impact factor: 5.722

8.  Identification of MMP9 as a novel key gene in mantle cell lymphoma based on bioinformatic analysis and design of cyclic peptides as MMP9 inhibitors based on molecular docking.

Authors:  Wei Yan; Shawn Xiang Li; Minjie Wei; Hua Gao
Journal:  Oncol Rep       Date:  2018-09-05       Impact factor: 3.906

Review 9.  How Signaling Molecules Regulate Tumor Microenvironment: Parallels to Wound Repair.

Authors:  Peter Gál; Lenka Varinská; Lenka Fáber; Štepán Novák; Pavol Szabo; Petra Mitrengová; Andrej Mirossay; Pavel Mučaji; Karel Smetana
Journal:  Molecules       Date:  2017-10-26       Impact factor: 4.411

10.  Andecaliximab [Anti-matrix Metalloproteinase-9] Induction Therapy for Ulcerative Colitis: A Randomised, Double-Blind, Placebo-Controlled, Phase 2/3 Study in Patients With Moderate to Severe Disease.

Authors:  William J Sandborn; Bal R Bhandari; Charles Randall; Ziad H Younes; Tomasz Romanczyk; Yan Xin; Emily Wendt; Hao Chai; Matt McKevitt; Sally Zhao; John S Sundy; Satish Keshav; Silvio Danese
Journal:  J Crohns Colitis       Date:  2018-08-29       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.